AJNA BIOSCIENCES

Operating

AJNA BioSciences PBC

Healthcare · Biotech · Littleton, CO

Visit website

Transforming the $678B pharmaceutical industry with plant medicine

Post-money valuation ⓘ

$126.1M

As of Oct 2025 · from Reg CF Offering (2025) · pre-money + amount raised, not a traded price

Total raised

$2,274,362

Across 2 rounds since 2024

Latest share price

$4.83

Reg CF Offering (2025) offering price

Financials

FY2022–FY2025 · from SEC filings · hover any figure for its source

$415K

−$4.1M

2022

$4.6M

$9.4M

2023

$3.3M

−$2.4M

2024

$1.7M

−$3.8M

2025

RevenueNet income — beside revenue when positive, below the line when a loss

Metric

FY2022

FY2023

FY2024

FY2025

Income statement

Revenue

$415,364

$4,558,657

$3,267,479

$1,692,791

Cost of goods sold

$415,364

$4,558,657

$3,267,479

$1,692,791

Gross margin

Net income

-$4,066,700

$9,372,650

-$2,359,584

-$3,800,746

Taxes paid

$30,000

Balance sheet

Cash

$532,128

$984,298

$1,927,679

$368,452

Accounts receivable

$415,364

Total assets

$3,003,351

$13,306,444

$16,627,450

$13,800,386

Short-term debt

$1,176,130

$9,619,653

$512,725

$1,496,442

Long-term debt

$8,180,430

$715,011

$1,953,013

$385,819

Total liabilities

$9,356,560

$10,334,664

$2,465,738

$1,882,261

Other

Headcount

—

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Post-money = pre-money + amount raised · caps marked

$41.2M

post-money

$126.1M

post-money

AJNA BIOSCIENCES Preferred Stock 1

Reg CF Offering (2025)

A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.

Fundraising history

Reg CF Offering (2025)ClosedReg CF · Preferred Equity · via STARTENGINE PRIMARY LLC

Raised $1M / $1.5MInvestors 346Post-money $126.1M

AJNA BIOSCIENCES Preferred Stock 1ClosedReg CF · Preferred Equity · via WeFunder

Raised $1.2M / $1.2MInvestors 552Post-money $41.2M

Team

5 people

Joel Stanley

Chief Executive Officer

Leader in botanical drug innovation and CBD industry trailblazer. Scaled CBD category leader Charlotte's Web from 0 to IPO with $75M in annual revenue. Former Chairman at Charlotte’s Web.

Orrin Devinsky, MD

Chief Medical Advisor

Dr. Orrin Devinsky is a renowned neurologist and epilepsy specialist, serving as Director of the NYU Langone Comprehensive Epilepsy Center and Professor of Neurology, Neurosurgery, and Psychiatry at NYU Grossman School of Medicine. With decades of clinical and research experience, Dr. Devinsky has been a leading voice in advancing treatments for epilepsy and neurological disorders, including groundbreaking work on the use of cannabidiol (CBD) for seizure control. He has authored hundreds of scientific publications and is widely respected for his holistic approach to patient care and brain health.

Robert Judge

VP of Finance

In CFO roles for 30+ years in manufacturing, distribution, family office, and privately held businesses. Senior manager at KPMG working with public and private companies.

Scott Hansen, MBA

VP Operations + Quality

Development and QC Sandoz Pharmaceuticals, Director QC and R&D Charlotte's Web, VP QC and Regulatory Affairs Agricor/Botanacor

Jesse Stanley

Board Member

Original co-founder of Charlottes Web and co-founder of AJNA BioSciences. Worked in alternative medicine for last 15 years.

Reg CF annual-report compliance

Compliant

Filed 2 of 2 annual reports (FY2024–FY2025)

552 investors

holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

SEC filings

View all 11 filings on EDGAR

Form C-ARMay 13, 20260001900590-26-000003
EDGAR
Form C-UNov 13, 20250001900590-25-000002
EDGAR
Form C/ASep 10, 20250001665160-25-001419
EDGAR

Source: ManualCIK 0001900590DEShare price $4.83

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.